Weekly paclitaxel and gemcitabine chemot
β
Vera Hirsh; Renaud Whittom; Linda Ofiara; Pierre Desjardins; Joseph Ayoub; Danie
π
Article
π
2003
π
John Wiley and Sons
π
English
β 84 KB
π 2 views
## Abstract ## BACKGROUND The current doseβoptimizing Phase II study evaluated the effect of weekly paclitaxel and gemcitabine on the response rate and survival of patients with nonβsmall cell lung carcinoma (NSCLC) using dose modifications that permitted optimal treatment intensity. ## METHODS